The FDA gave orphan drug designation to Fountain Biopharma's FB825, an anti-CemX anti-allergic monoclonal antibody being developed as a treatment for patients with hyper IgE syndrome.
FDA grants orphan status to Fountain's hyper IgE syndrome drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.